1 min read
Evotec Announces Second FDA IND Acceptance in Bristol Myers Partnership
The Nov. 19 acceptance advances the strategic protein degradation partnership; the candidate was not identified.

Evotec announced that its strategic protein degradation partnership with Bristol Myers Squibb received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration on Nov. 19, 2026.